InvivoSciences, Inc.
Wednesday, June 05, 2024
Company Presentation
![Cardiovascular](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/BIO-track-icon_Workforce_MTC.png)
Company Presentation Theater 3
InvivoSciences, Inc. (IVS) is a pre-clinical-stage biotech company focused on developing therapies for cardiovascular and cardiometabolic diseases. Our Kokordia™ technology platform integrates patient-derived micro heart models (NuHeart™) and AI-assisted clinical trial enrichment diagnostics. Kokordia™ improves the efficacy of clinical trials cost-efficiently by improving the statistical significance with fewer patients, supporting precision medicine in the cardiovascular domain. Our leading pipeline, IVS201, targets a specific heart failure subtype with preserved ejection fraction (HFpEF) identified through Kokordia™. It addresses interstitial cardiac fibrosis, normalizing diastolic stiffness and hyper-contractility. IVS is actively seeking funding and partnerships to advance its heart failure drug development programs and support partners’ precision medicine initiatives.
![InvivoSciences, Inc.](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1822780-1-JPG.png)
Company Website:
http://WWW.Invivosciences.com
Lead Product in Development:
IVS201
Number Of Unlicensed Products (For Which You Are Seeking Partners):
7
Company HQ City
Madison
Company HQ State
Wisconsin
Company HQ Country
United States
CEO/Top Company Official
Ayla Annac, mba
Development Phase of Primary Product
Pre-Clinical
Primary Speaker